Parexel appoints Gwyn Bebb to lead oncology clinical development

Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Sun Pharma and Pharmazz ink agreement for introducing Tyvalzi in India

Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)

SMi Systems secures UK patent for breakthrough single molecule imaging capabilities

The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics

Takara Bio Europe launches high-quality enzymes suitable for pre-clinical mRNA vaccine

AI to transform all processes in drug development by 2026, predicts CPHI Report

In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent